-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 7, 2021, Harbin Pharmaceutical Group stated that its subsidiary Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co.
, Ltd.
received the "Drug Supplementary Application Approval Document" for Simvastatin tablets issued by the National Medical Products Administration, and the drug passed Consistency evaluation of the quality and efficacy of generic drugs
.
Simvastatin tablets are commonly used oral hypolipidemic drugs, the main indications are:
(1) Hyperlipidemia
.
① For patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or mixed hypercholesterolemia, when diet control and other non-drug treatments are not ideal, simvastatin can be used to reduce elevated total Cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides, and simvastatin raises high-density lipoprotein cholesterol, thereby reducing the ratio of low-density lipoprotein/high-density lipoprotein and total cholesterol/high-density lipoprotein
(2) Coronary heart disease
.
① Reduce the risk of death
According to relevant national policies, drug varieties that have passed the consistency evaluation of the quality and efficacy of generic drugs will receive greater support in areas such as medical insurance payment and procurement by medical institutions